- Home
- ASH vs SUPN Comparison
ASH vs SUPN Comparison
Compare ASH & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASH
- SUPN
- Stock Information
- Founded
- ASH 1924
- SUPN 2005
- Country
- ASH United States
- SUPN United States
- Employees
- ASH N/A
- SUPN N/A
- Industry
- ASH Specialty Chemicals
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- ASH Consumer Discretionary
- SUPN Health Care
- Exchange
- ASH Nasdaq
- SUPN Nasdaq
- Market Cap
- ASH 2.2B
- SUPN 2.6B
- IPO Year
- ASH N/A
- SUPN 2012
- Fundamental
- Price
- ASH $52.01
- SUPN $46.24
- Analyst Decision
- ASH Buy
- SUPN Strong Buy
- Analyst Count
- ASH 8
- SUPN 4
- Target Price
- ASH $60.14
- SUPN $63.25
- AVG Volume (30 Days)
- ASH 921.4K
- SUPN 1.2M
- Earning Date
- ASH 11-04-2025
- SUPN 11-04-2025
- Dividend Yield
- ASH 3.21%
- SUPN N/A
- EPS Growth
- ASH N/A
- SUPN N/A
- EPS
- ASH N/A
- SUPN N/A
- Revenue
- ASH $1,824,000,000.00
- SUPN $681,539,000.00
- Revenue This Year
- ASH $3.18
- SUPN $8.29
- Revenue Next Year
- ASH $3.72
- SUPN $22.72
- P/E Ratio
- ASH N/A
- SUPN N/A
- Revenue Growth
- ASH N/A
- SUPN 4.54
- 52 Week Low
- ASH $45.21
- SUPN $29.16
- 52 Week High
- ASH $80.94
- SUPN $57.65
- Technical
- Relative Strength Index (RSI)
- ASH 57.52
- SUPN 45.50
- Support Level
- ASH $48.00
- SUPN $44.37
- Resistance Level
- ASH $51.19
- SUPN $46.47
- Average True Range (ATR)
- ASH 1.67
- SUPN 1.67
- MACD
- ASH 0.09
- SUPN -0.19
- Stochastic Oscillator
- ASH 74.23
- SUPN 62.09
About ASH Ashland Inc.
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.